Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ANG Lifesciences India's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹-169.8 Mil. ANG Lifesciences India's average total tangible assets for the quarter that ended in Jun. 2026 was ₹2,089.5 Mil. Therefore, ANG Lifesciences India's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was -8.12%.
The historical rank and industry rank for ANG Lifesciences India's Return-on-Tangible-Asset or its related term are showing as below:
BOM:540694'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -5.26 Med: 6.2 Max: 18.56
Current: -4.88
During the past 13 years, ANG Lifesciences India's highest Return-on-Tangible-Asset was 18.56%. The lowest was -5.26%. And the median was 6.20%.
BOM:540694's Return-on-Tangible-Asset is ranked worse than 71.37% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.935
vs BOM:540694: -4.88
ANG Lifesciences India (BOM:540694) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ANG Lifesciences India Return-on-Tangible-Asset Related Terms
ANG Lifesciences India Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ANG Lifesciences India's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANG Lifesciences India Return-on-Tangible-Asset Chart
BOM:540694 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANG Lifesciences India Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ANG Lifesciences India's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of -8.12% mean?
ANG Lifesciences India (BOM:540694) has a Return-on-Tangible-Asset of -8.12% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ANG Lifesciences India and its competitors. According to the industry distribution chart, ANG Lifesciences India ranks #718 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 71.4%.
Is ANG Lifesciences India's Return-on-Tangible-Asset too high?
ANG Lifesciences India's current Return-on-Tangible-Asset is -8.12%. Based on the distribution chart, ANG Lifesciences India ranks #718 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, ANG Lifesciences India has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, ANG Lifesciences India ranks #718 out of 1006 companies for Return-on-Tangible-Asset. This places ANG Lifesciences India in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.94, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ANG Lifesciences India and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANG Lifesciences India's current Return-on-Tangible-Asset is -8.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Fairly Valued. The stock's GF Value™ is ₹29.90, compared to a current price of ₹27.92 — trading 6.6% below its estimated fair value. The current Return-on-Tangible-Asset is -8.12%. ANG Lifesciences India's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current Return-on-Tangible-Asset is -8.12% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be undervalued.
The current stock price of ₹27.92 is trading 6.6% below its estimated GF Value™ of ₹29.90.
GuruFocus considers ANG Lifesciences India to be Fairly Valued.
Key valuation signals for BOM:540694:
Return-on-Tangible-Asset: -8.12%
GF Value™: ₹29.90 vs. price of ₹27.92 (6.6% below fair value)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
63GF Score
Get the complete analysis for BOM:540694
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
